PMC3499678

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline ADHD severity predicted greater reduction in ADHD symptoms and greater odds of achieving a 50% reduction in substance use, regardless of medication assignment.

Effect: improvement; regression coefficient = 0.64 (ADHD change); OR=1.06 (SUD responder); CI: 95% CI: 1.01 to 1.11 (SUD responder)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)

Greater baseline substance use severity predicted less improvement in ADHD symptoms and fewer negative urine drug screens during 16 weeks of treatment, regardless of medication assignment.

Effect: decline; regression coefficient = -0.35 (ADHD change); regression coefficient = -0.08 (negative urine samples)